Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration
Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best small cap stocks with biggest upside potential.
Janux Therapeutics Inc. (JANX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 11,189,693 | $258,481,908 | 4.35% | |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 2,525,000 | $58,327,500 | -31% | 0.1% |
| 3. | Point72 Asset Management Steve Cohen | 2,143,900 | $49,524,090 | +470% | 0.1% |
| 4. | Cormorant Asset Management Bihua Chen | 1,500,000 | $34,650,000 | -25% | 2.58% |
| 5. | EcoR1 Capital Oleg Nodelman | 1,469,818 | $33,952,796 | 2.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.02 | 110,206 | $3,418,590.12 | 10,141,287 | 2025-03-07 | Filing | |
| $30.78 | 372,093 | $11,453,022.54 | 10,031,081 | 2025-03-06 | Filing | |
| $31.30 | 37,455 | $1,172,341.50 | 9,658,988 | 2025-03-05 | Filing | |
| $30.56 | 304,287 | $9,299,010.72 | 9,621,533 | 2025-03-05 | Filing | |
| $44.75 | 1,200,000 | $53,700,000.00 | 9,317,246 | 2024-10-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.60 | 400 | $13,041.36 | 82,139 | 2025-05-01 | Filing | |
| $31.95 | 2,933 | $93,703.19 | 82,539 | 2025-05-01 | Filing | |
| $30.00 | 3,334 | $100,020.00 | 82,139 | 2025-04-21 | Filing | |
| $32.85 | 901 | $29,598.66 | 82,139 | 2025-03-03 | Filing | |
| $31.88 | 2,433 | $77,575.72 | 83,040 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,888,742 | $205,329,932 | 0.01% | |
| 2. | 4,460,332 | $103,045,329 | 0.05% | |
| 3. | 3,402,847 | $78,605,766 | 0% | |
| 4. | 2,920,258 | $67,457,960 | 2.88% | |
| 5. | 2,189,428 | $50,575,788 | 0% |
News See All
9 Best Small Cap Stocks with Biggest Upside Potential
On August 14, Jonathan Krinsky of BTIG, joined 'Closing Bell' on CNBC to discuss whether the recent rally in small cap stocks is sustainable.
JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target
Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 14, JonesTrading analyst Soumit Roy maintained a bullish stance on Janux Therapeutics, Inc.
13 Small Cap Stocks Analysts Are Bullish On
On June 23, Jason Thomas, Carlyle's head of global research and investment strategy, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the market and economy in light of the recent financial...
Unknown Billionaire Phill Gross’ 10 Stock Picks with Huge Upside Potential
Phillip “Phill” Gross is a seasoned investor and influential figure in the world of institutional asset management, best known as the Co-founder, Managing Director, and Healthcare Portfolio Manager...
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential
On April 24, Jill Carey Hall, BofA Securities head of U.S. small/mid-cap strategy, appeared on 'Closing Bell' to talk about the impact of tariffs on small caps.
10 Best Small-Cap Stocks to Buy Before They Explode
Since the announcement of tariffs, investors have been concerned regarding the market volatility.
12 Best Up and Coming Stocks to Buy According to Wall Street Analysts
Tom Lee, Fundstrat managing partner, joined CNBC's 'Closing Bell' on March 22 to discuss the current market sentiment.
10 Worst High-Risk High-Reward Growth Stocks To Buy
On March 14, Tom Lee managing partner and head of research at Fundstrat Global Advisors appeared on a CNBC interview to talk about how the markets react to crises and what approach investors should take...
10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.